Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
Metronomic Therapy: Where are we Standing?
Joaquim Henriques
Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
Read
The use of cytotoxic drugs to treat cancer has been part of the therapeutic arsenal in oncology in the last 50-60 years. Despite the use of this compounds based in the concept of the “maximum tolerated dose” (MTD), in most malignancies the cure or even the long term control of the cancer it is not achieved. The shift on the paradigm concept from “the tumor cell” to the “tumor microenvironment”, considering cancer as a complex disease interaction between cancer cells, host immune system and tumor microenvironment has led to rethinking the way we approach, nowadays, cancer treatment, either in humans or veterinary patients. The use of MTD aims to destroy rapidly dividing cells and considers an interval between dose administrations to allow the bone marrow and other chemo-sensitive cells from the organism to recover. This interval, can also permit the recovery of cancer cells and consequently, the regrowth of the tumor. In the early years of this century, a new approach on a continuous scheduling and low dosing of cytotoxic drugs appeared and the results were enthusiastic enough to carry on further use and research on what was defined as low dose metronomic chemotherapy (LDM). This concept ,uses smaller doses of cytotoxic drugs, on a continuous long time period with no breaks, a shift from high-dose to high-time chemotherapy administration became the DNA of metronomic chemotherapy. [...]
Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
About
Affiliation of the authors at the time of publication
OnevetGroup Onevet Hospital Veterinário Berna Av. De Berna, 35- Lisboa Portugal
Comments (0)
Ask the author
0 comments